Cyclin-dependent kinase

Results: 94



#Item
31Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells

Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2014-11-27 08:36:24
32Microsoft Word - Publication2004

Microsoft Word - Publication2004

Add to Reading List

Source URL: www.mnc.ust.hk

Language: English - Date: 2009-07-31 04:22:31
33Preferential Fas-mediated apoptotic execution at G1 phase: the resistance of mitotic cells to the cell death

Preferential Fas-mediated apoptotic execution at G1 phase: the resistance of mitotic cells to the cell death

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2012-05-24 05:56:10
34Microsoft Word - Publication2002

Microsoft Word - Publication2002

Add to Reading List

Source URL: www.mnc.ust.hk

Language: English - Date: 2009-07-31 04:22:31
35CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo Eun Yong Shim,1,2 Amy K. Walker,1,2 Yang Shi,2 and T. Keith Blackwell1,2,3 1

CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo Eun Yong Shim,1,2 Amy K. Walker,1,2 Yang Shi,2 and T. Keith Blackwell1,2,3 1

Add to Reading List

Source URL: blackwellweb.joslin.harvard.edu

Language: English - Date: 2003-07-07 15:30:54
36Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,

Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,

Add to Reading List

Source URL: astx.com

Language: English - Date: 2012-12-13 18:06:00
37AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C

AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C

Add to Reading List

Source URL: astx.com

Language: English
38AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2.  INTRODUCTION

AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION

Add to Reading List

Source URL: astx.com

Language: English
39OPEN  Citation: Cell Death and Disease[removed], e693; doi:[removed]cddis[removed] & 2013 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis

OPEN Citation: Cell Death and Disease[removed], e693; doi:[removed]cddis[removed] & 2013 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2013-06-27 09:56:01
40ABSTRACT # 491 NCIC CTG IND.177: Phase I Study of AT7519M Given as a Short Infusion Twice Weekly S. J. Hotte, E. X. Chen, L. McIntosh, H. Hirte, S. Turner, A. Jarvi, V. Lock, L. Seymour

ABSTRACT # 491 NCIC CTG IND.177: Phase I Study of AT7519M Given as a Short Infusion Twice Weekly S. J. Hotte, E. X. Chen, L. McIntosh, H. Hirte, S. Turner, A. Jarvi, V. Lock, L. Seymour

Add to Reading List

Source URL: astx.com

Language: English - Date: 2012-12-13 18:06:00